Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6045522 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL6045696 | 0.77 | — | — | |
| SCHEMBL22123614 | 0.69 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL26940413 | 0.69 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL15044657 | 0.67 | — | — | |
| SCHEMBL22124371 | 0.66 | EPHX1 (0.35) | SMN1; SMN2 | |
| SCHEMBL9599191 | 0.66 | — | — | |
| SCHEMBL307800 | 0.65 | CA12 (0.38) | — | |
| SCHEMBL8355844 | 0.65 | CA12 (0.38) | — | |
| SCHEMBL9079974 | 0.65 | CA12 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252774-A1 | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases | NEW JERSEY, UNIVERSITY OF MEDICINE AND DENTISTRY OF | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252774-A1 | Regulation of type 5 adenylyl cyclase for treatment of neurodegenerative and cardiac diseases | ADCY5, ADCY6, ADCY2 | SMN1; SMN2 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.